SRZNWSurrozen Inc. Warrant
Data unavailable—Mkt Cap: —P/E: —54d ago
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target variou…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)11.51M $
Gross Profit-23.07M $
Net Income (TTM)-242.03M $
Revenue/Share1.142 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-5.70
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin-200.38%
Oper. Margin-207.40%
EBITDA Margin0.00%
Profit Margin-6960.77%
ROE128.90%
ROA-245.15%
Growth
Revenue Growth408.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.24M $
CapEx (TTM)128.00K $
FCF Margin-188.96%
FCF Yield—
Net Debt-95.72M $
Net Debt/EBITDA2.17
Balance Sheet
Debt/Equity-0.04
Current Ratio12.14
Quick Ratio11.88
Book Value/Sh-18.6030 USD
Cash/Share8.682 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float4.62M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.56
S&P 52W Chg15.96%
Avg Vol (30d)—
Avg Vol (10d)—
Technical Indicators
RSI (14)24.9
MACD-0.0015
MACD Signal-0.0006
MACD Hist.-0.0010
BB Upper0.0224 USD
BB Middle0.0157 USD
BB Lower0.0089 USD
BB Width86.16%
ATR (14)0.0024 USD
Vol Ratio (20d)10.98x